Hidradenitis suppurativa in Malaysia: Expert consensus on diagnosis, management, and therapeutic strategies

Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory skin disorder, affecting intertriginous areas and characterized by painful nodules, abscesses, fistulae, and scarring. Despite its impact on patients’ quality of life (QoL), HS remains underdiagnosed and mismanaged due to its heterogeneous clinical presentation. A panel of 14 Malaysian dermatologists, HS special interest group, developed a set of consensus-based recommendations on diagnosis, disease assessment, comorbidities, treatment, and follow-up care to improve HS management. A modified Delphi process was utilized to draft and finalize statements based on evidence sourced from literature between 2013 and 2023. The consensus highlights the importance of early recognition of HS clinical signs, differential diagnosis, and the use of validated tools such as Hurley staging, International HS Severity Score System, and Dermatology Life Quality Index to assess disease severity and QoL. Treatment recommendations for HS were stratified by disease severity, including topical, systemic, and biologic therapies, and surgical interventions for advanced cases. Adalimumab and secukinumab are currently the only approved biologics in Malaysia, showing sustained efficacy in moderate-to-severe HS. Adjunctive therapies such as zinc supplementation, lifestyle modifications, and wound care are also recommended. The consensus emphasizes a multidisciplinary approach to address the multifaceted nature of HS and optimize long-term outcomes, and aims to standardize HS care in Malaysia, promote early intervention, and enhance QoL for affected patients.